Compare FLYW & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | NUVB |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2021 | N/A |
| Metric | FLYW | NUVB |
|---|---|---|
| Price | $18.55 | $5.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $16.21 | $11.38 |
| AVG Volume (30 Days) | 2.6M | ★ 8.5M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $623,025,000.00 | N/A |
| Revenue This Year | $19.68 | $203.82 |
| Revenue Next Year | $15.25 | $58.18 |
| P/E Ratio | $183.30 | ★ N/A |
| Revenue Growth | ★ 26.59 | N/A |
| 52 Week Low | $10.11 | $2.06 |
| 52 Week High | $18.92 | $9.75 |
| Indicator | FLYW | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 56.87 |
| Support Level | $13.15 | $4.13 |
| Resistance Level | N/A | $6.06 |
| Average True Range (ATR) | 0.76 | 0.40 |
| MACD | 0.27 | -0.02 |
| Stochastic Oscillator | 88.11 | 42.81 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.